First drug-eluting contact lens approved in Japan

Video

Acuvue Theravision with Ketotifen from Johnson & Johnson Vision is the first entry into an anticipated category of drug-eluting contact lenses.

Acuvue Theravision with Ketotifen from Johnson & Johnson Vision is the first entry into an anticipated category of drug-eluting contact lenses. This lens was recently approved in Japan for vision correction and allergy symptom relief. Brian Pall, OD, MS, FAAO, director of clinical science at Johnson & Johnson Vision Care, discusses the lens and its technology.

Recent Videos
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).
Dr Jamie Kuzniar discusses higher order aberrations and premium scleral lenses
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
In a study, a xenon slide illuminator was employed to mimic natural outdoor colors, allowing researchers to test brightness perception using a brightness-matching method, explains Billy R. Hammond.
Christi Closson, OD, FAAO, provides insight on what other ODs learned about Johnson & Johnson's contact lens technology.
© 2025 MJH Life Sciences

All rights reserved.